Presentan en Cuba potencialidades de péptido antitumoral
(Tomado de Prensa Latina)
(English version at the end of the text)
Investigaciones realizadas en Cuba con el péptido RjLB-14 permitieron determinar sus efectos antitumorales en modelos preclínicos, explicó hoy José A. Fraga, director del Grupo Empresarial Labiofam.
Más de 14 años de intenso trabajo validan este producto, obtenido de fuentes naturales, que responde a una amplia variedad de tumores sólidos, manifestó Fraga durante un simposio internacional que sobre el tema sesiona en el Hotel Nacional, en esta capital.
Presented in Cuba potential antitumor peptide
(Taken from Prensa Latina)
Research in Cuba with peptide RjLB-14 allowed to determine their antitumor effects in preclinical models, said today José A. Fraga, director of Grupo Empresarial Labiofam.
Over 14 years of hard work validated product obtained from natural sources, which responds to a wide variety of solid tumors, Fraga said during an international symposium on the subject meets at the Hotel Nacional in Havana.
It is an active ingredient, an ideal candidate with great potential in the treatment of cancer, which is still working to determine toxicity and mechanism of action, and achieve new formulations, he added.
We are facing an effective tool, "raw material" available to all institutions that want to develop the production of an antitumor drug, based on its active principle, said.
Representatives from Russia, Ukraine, Italy and Chile, among other nations participating in the meeting, which also aims to build partnerships with laboratories and pharmaceutical, biotechnology and medical, he said.
In that case is the engineer Roberto Comini, President of the Italian company FarmaVenda, who told Prensa Latina interest in the peptide, which is considered an open door with large research and future possibilities. (Translated by Google)